查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446442

北美分子診斷市場規模、佔有率、趨勢分析報告：按產品、測試地點、技術、應用、國家和細分市場預測，2024-2030

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Others), By Test Location, By Technology (PCR, ISH, INAAT, Sequencing), By Application, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

北美分子診斷市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，2030年北美分子診斷市場規模預計將達到72.3億美元，2024年至2030年複合年成長率為4.2%。

技術先進產品的推出預計將帶動北美市場的發展。分子診斷技術的進步使得許多疾病得以早期發現，減少了嚴重的經濟和社會負擔的可能性。分子診斷技術利用PCR、定序和遺傳技術來實現癌症、遺傳疾病和感染疾病的早期診斷。

阿茲海默症、透納氏症、帕金森氏症等慢性疾病以及感染疾病和遺傳疾病的盛行率不斷上升，預計將在預測期內提振市場需求。據美國疾病管制與預防中心 (CDC) 稱，美國每年有十分之七的死亡病例是由癌症、糖尿病、慢性腎臟病和呼吸系統疾病等慢性病造成的。此外，甲型和乙型流感等疾病的增加預計也將推動市場成長。例如，根據美國疾病管制與預防中心 (CDC) 估計，2021-2022 年流感季節期間將有 900 萬人感染流感。

用於分子診斷臨床研究的外部資金的增加預計將推動市場的發展。資金籌措在產品開發過程中扮演重要角色。例如，2023 年 4 月，Promega 公司宣佈在 2023 年津貼15,000 美元，用於使用 qPCR 的學術生命科學研究。同樣，2023 年 6 月，Accelerate Diagnostics, Inc. 獲得了 2,400 萬美元，用於加速其 Wave 平台和新型快速測試的開發。透過這些舉措，預計中小企業將參與新分子診斷測試的開發。

北美分子診斷領域的主要企業繼續努力透過推出新產品並以更先進、更有效率的產品滿足買家不斷變化的需求來獲得競爭優勢。例如，2022年11月，丹納赫子公司Cepheid推出了多重陰道檢測組合（MVP），這是一種PCR檢測，可檢測滴蟲病、細菌性念珠菌症和外陰陰道念珠菌病等多種疾病。

此外，製造商和公司之間為開發新型療法而加強的策略合作夥伴關係預計將推動市場成長。例如，2023年2月，Thermo Fisher Scientific Inc.與MyLab合作購買了針對結核病和HIV等多種感染疾病的RT-PCR套件。此外，2023 年 1 月，QIAGEN 和 Helix 達成獨家合作，以增強遺傳疾病的次世代定序儀伴同性伴隨診斷。

北美分子診斷市場報告亮點：

  • 以產品來看，由於效率和成本效益的提高，試劑細分市場在2023年佔據北美分子診斷領域最大的銷售佔有率。
  • 由於市場滲透率高、測試量大，2023年北美分子診斷市場由中心實驗室領域主導。
  • 從技術上來看，PCR領域將在2023年主導北美分子診斷市場，是醫師和病患臨床診斷最首選的技術。
  • 由於北美感染疾病高發生，感染疾病領域引領2023年應用領域。
  • 由於有利的報銷政策、主要參與者在當地的存在以及成熟的醫療基礎設施，美國在該區域市場佔據主導地位。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影響分析

第4章北美分子診斷市場：產品業務分析

  • 北美分子診斷市場：產品變異分析
  • 裝置
  • 試劑
  • 其他

第5章北美分子診斷市場：測試地點的業務分析

  • 北美分子診斷市場：測試位置變化分析
  • 照護端
  • 自我測試或商店測試
  • 中央研究院

第6章北美分子診斷市場：技術業務分析

  • 北美分子診斷市場：技術變遷分析
  • PCR
  • 原位雜合反應(ISH)
  • 恒溫核酸增幅技術（INAAT）
  • 晶片和微陣列
  • 質譜
  • 順序
  • 轉錄媒介增幅(TMA)
  • 其他

第7章北美分子診斷市場：應用業務分析

  • 北美分子診斷市場：應用變化分析
  • 腫瘤學
  • 藥物基因組學
  • 感染疾病
  • 基因檢測
  • 神經系統疾病
  • 循環系統疾病
  • 微生物學
  • 其他

第8章北美分子診斷市場：國家業務分析

  • 北美洲
    • 美國
    • 加拿大

第9章北美分子診斷市場：競爭形勢

  • 參與企業
    • BD
    • Bio-Rad Laboratories, Inc.
    • Abbott
    • Agilent Technologies, Inc.
    • Danaher
    • Hologic Inc. (Gen Probe)
    • Illumina, Inc.
    • Johnson & Johnson Services, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche, Ltd.
  • 參與企業概況
  • 財務績效
  • 產品基準評效
  • 2023 年公司市場佔有率分析
  • 策略規劃

第10章分析師的觀點

Product Code: GVR-1-68038-073-6

North America Molecular Diagnostics Market Growth & Trends:

The North America molecular diagnostics market size is expected to reach USD 7.23 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of technologically advanced products is expected to drive the market in North America. Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens. Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.

The rise in the prevalence of chronic & infectious diseases and genetic disorders, such as Alzheimer's disease, Turner syndrome, & Parkinson's disease, is expected to boost the market demand during the forecast period. According to the CDC, chronic diseases such as cancer & diabetes and chronic kidney & respiratory diseases are accountable for 7 in 10 deaths in the U.S. each year. Around 6 out of 10 adults are likely to suffer from a chronic disease in the U.S. In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth. For instance, according to the CDC, in the flu season of 2021-2022, influenza was estimated to affect nine million people.

An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market. Funding plays a significant role in the product development process. For instance, in April 2023, Promega Corporation announced to grant of USD 15,000 in 2023 in academic life sciences research using qPCR. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of Wave platform and novel rapid testing. Such initiatives are expected to encourage SMEs to be involved in the development of novel molecular diagnostic tests.

Key companies are making continuous efforts to launch new products in North America molecular diagnostics and gain a competitive edge by meeting the changing needs of buyers toward more advanced & efficient products. For instance, in November 2022, Cepheid, a Danaher subsidiary, launched Multiplex Vaginal Panel (MVP), a PCR test to detect various conditions, such as trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis.

Furthermore, increasing strategic partnerships among manufacturers and companies for developing novel therapeutics is anticipated to drive market growth. For instance, in February 2023, Thermo Fisher Scientific Inc.partnered with MyLab to procure RT-PCR kits for various infectious diseases, such as tuberculosis & HIV. Moreover, in January 2023, QIAGEN and Helix formed an exclusive alliance to enhance next-generation sequencing companion diagnostics in genetic disorders.

North America Molecular Diagnostics Market Report Highlights:

  • Based on the product, the reagents segment accounted for the largest revenue share of North America molecular diagnostics in 2023 owing to improved efficiency and cost-effectiveness
  • The central laboratories segment dominated the North America molecular diagnostics in 2023 owing to high market penetration and large procedure volumes
  • Based on technology, the PCR segment dominated the North America molecular diagnostics in 2023 and is the most preferred technology amongst doctors and patients for clinical diagnostics
  • The infectious disease segment led the application segment in 2023, attributable to North America's high incidence of infectious diseases
  • The U.S. dominated the regional market due to favorable reimbursement policies, the local presence of leading players, and the presence of well-established healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product segment
      • 1.1.1.2. Test Location segment
      • 1.1.1.3. Technology segment
      • 1.1.1.4. Application segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Test Location Snapshot
  • 2.3. Technology and Application Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in geriatric population
      • 3.2.1.2. Introduction of technologically advanced products
      • 3.2.1.3. Increase in demand for point-of-care testing
      • 3.2.1.4. Growing prevalence of target diseases
      • 3.2.1.5. Increasing external funding for R&D
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of ambiguous regulatory framework
      • 3.2.2.2. High prices of molecular diagnostics tests
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Molecular Diagnostics Market: Product Business Analysis

  • 4.1. North America Molecular Diagnostics Market: Product Movement Analysis
  • 4.2. Instruments
    • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Reagents Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. North America Molecular Diagnostics Market: Test Location Business Analysis

  • 5.1. North America Molecular Diagnostics Market: Test Location Movement Analysis
  • 5.2. Point-of-Care
    • 5.2.1. Point-of-Care Market, 2018 - 2030 (USD Million)
  • 5.3. Self-test or Over the Counter
    • 5.3.1. Self-test or Over the Counter Market, 2018 - 2030 (USD Million)
  • 5.4. Central Laboratories
    • 5.4.1. Central Laboratories Market, 2018 - 2030 (USD Million)

Chapter 6. North America Molecular Diagnostics Market: Technology Business Analysis

  • 6.1. North America Molecular Diagnostics Market: Technology Movement Analysis
  • 6.2. PCR
    • 6.2.1. PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.1. PCR, by Type
      • 6.2.1.1.1. PCR, by Type Market, 2018 - 2030 (USD Million)
      • 6.2.1.1.1.1. Multiplex PCR
      • 6.2.1.1.1.1.1. Multiplex PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.1.1.2. Other PCR
      • 6.2.1.1.1.2.1. Other PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.2. PCR, by Procedure
      • 6.2.1.2.1. PCR, by Procedure Market, 2018 - 2030 (USD Million)
      • 6.2.1.2.1.1. Nucleic Acid Extraction
      • 6.2.1.2.1.1.1. Nucleic Acid Extraction Market, 2018 - 2030 (USD Million)
      • 6.2.1.2.1.2. Others
      • 6.2.1.2.1.2.1. Others Market, 2018 - 2030 (USD Million)
      • 6.2.1.3. PCR, by Product
      • 6.2.1.3.1. PCR, by Product Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.1. Instruments
      • 6.2.1.3.1.1.1. Instruments Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.2. Reagents
      • 6.2.1.3.1.2.1. Reagents Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.3. Others
      • 6.2.1.3.1.3.1. Others Market, 2018 - 2030 (USD Million)
  • 6.3. In Situ Hybridization (ISH)
    • 6.3.1. In Situ Hybridization (ISH) Market, 2018 - 2030 (USD Million)
    • 6.3.2. Instruments
      • 6.3.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.3.3. Reagents
      • 6.3.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.3.4. Others Market, 2018 - 2030 (USD Million)
      • 6.3.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 6.4.1. Isothermal Nucleic Acid Amplification Technology (INAAT) Market, 2018 - 2030 (USD Million)
    • 6.4.2. Instruments
      • 6.4.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.4.3. Reagents
      • 6.4.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.4.4. Others Market, 2018 - 2030 (USD Million)
      • 6.4.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.5. Chips and Microarrays
    • 6.5.1. Chips and Microarrays Market, 2018 - 2030 (USD Million)
    • 6.5.2. Instruments
      • 6.5.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.5.3. Reagents
      • 6.5.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.5.4. Others Market, 2018 - 2030 (USD Million)
      • 6.5.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.6. Mass Spectroscopy
    • 6.6.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
    • 6.6.2. Instruments
      • 6.6.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.6.3. Reagents
      • 6.6.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.6.4. Others Market, 2018 - 2030 (USD Million)
      • 6.6.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.7. Sequencing
    • 6.7.1. Sequencing Market, 2018 - 2030 (USD Million)
    • 6.7.2. Instruments
      • 6.7.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.7.3. Reagents
      • 6.7.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.7.4. Others Market, 2018 - 2030 (USD Million)
      • 6.7.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.8. Transcription Mediated Amplification (TMA)
    • 6.8.1. Transcription Mediated Amplification (TMA) Market, 2018 - 2030 (USD Million)
    • 6.8.2. Instruments
      • 6.8.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.8.3. Reagents
      • 6.8.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.8.4. Others Market, 2018 - 2030 (USD Million)
      • 6.8.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market, 2018 - 2030 (USD Million)
    • 6.9.2. Instruments
      • 6.9.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.9.3. Reagents
      • 6.9.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.9.4. Others Market, 2018 - 2030 (USD Million)
      • 6.9.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. North America Molecular Diagnostics Market: Application Business Analysis

  • 7.1. North America Molecular Diagnostics Market: Application Movement Analysis
  • 7.2. Oncology
    • 7.2.1. Oncology Market, 2018 - 2030 (USD Million)
    • 7.2.2. Breast Cancer
      • 7.2.2.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.3. Prostate Cancer
      • 7.2.3.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.4. Colorectal Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.4.1. Colorectal Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.5. Cervical Cancer
      • 7.2.5.1. Cervical Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.6. Kidney Cancer
      • 7.2.6.1. Kidney Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.7. Liver Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.7.1. Liver Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.8. Blood Cancer
      • 7.2.8.1. Blood Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.9. Lung Cancer
      • 7.2.9.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.10. Other Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.10.1. Other Cancer Market, 2018 - 2030 (USD Million)
  • 7.3. Pharmacogenomics
    • 7.3.1. Pharmacogenomics Market, 2018 - 2030 (USD Million)
  • 7.4. Infectious Diseases
    • 7.4.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
    • 7.4.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
      • 7.4.2.1. Methicillin-resistant Staphylococcus Aureus (MRSA) Market, 2018 - 2030 (USD Million)
    • 7.4.3. Clostridium Difficile
      • 7.4.3.1. Clostridium Difficile Market, 2018 - 2030 (USD Million)
    • 7.4.4. Vancomycin-resistant Enterococci (VRE)
      • 7.4.4.1. Vancomycin-resistant Enterococci (VRE) Market, 2018 - 2030 (USD Million) Instruments
    • 7.4.5. Carbapenem-resistant Bacteria
      • 7.4.5.1. Carbapenem-resistant Bacteria Market, 2018 - 2030 (USD Million)
    • 7.4.6. Flu
      • 7.4.6.1. Flu Market, 2018 - 2030 (USD Million)
    • 7.4.7. Candida Market, 2018 - 2030 (USD Million)
      • 7.4.7.1. Candida Market, 2018 - 2030 (USD Million)
    • 7.4.8. Tuberculosis and Drug-resistant TBA
      • 7.4.8.1. Tuberculosis and Drug-resistant TBA Market, 2018 - 2030 (USD Million)
    • 7.4.9. Meningitis
      • 7.4.9.1. Meningitis Market, 2018 - 2030 (USD Million)
    • 7.4.10. Gastrointestinal Panel Testing
      • 7.4.10.1. Gastrointestinal Panel Testing Market, 2018 - 2030 (USD Million)
    • 7.4.11. Chlamydia
      • 7.4.11.1. Chlamydia Market, 2018 - 2030 (USD Million)
    • 7.4.12. Gonorrhea
      • 7.4.12.1. Gonorrhea Market, 2018 - 2030 (USD Million)
    • 7.4.13. HIV
      • 7.4.13.1. HIV Market, 2018 - 2030 (USD Million)
    • 7.4.14. Hepatitis C
      • 7.4.14.1. Hepatitis C Market, 2018 - 2030 (USD Million)
    • 7.4.15. Hepatitis B
      • 7.4.15.1. Hepatitis B Market, 2018 - 2030 (USD Million)
    • 7.4.16. Others Infectious Diseases
      • 7.4.16.1. Other Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 7.5. Genetic Testing
    • 7.5.1. Genetic Testing Market, 2018 - 2030 (USD Million)
    • 7.5.2. Newborn Screening
      • 7.5.2.1. Newborn Screening Market, 2018 - 2030 (USD Million)
    • 7.5.3. Predictive and Presymptomatic Testing
      • 7.5.3.1. Predictive and Presymptomatic Market, 2018 - 2030 (USD Million)
    • 7.5.4. Other Genetic Testing Market, 2018 - 2030 (USD Million) Instruments
      • 7.5.4.1. Other Genetic Testing Market, 2018 - 2030 (USD Million)
  • 7.6. Neurological Disease
    • 7.6.1. Neurological Disease Market, 2018 - 2030 (USD Million)
  • 7.7. Cardiovascular Disease
    • 7.7.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
  • 7.8. Microbiology
    • 7.8.1. Microbiology Market, 2018 - 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. North America Molecular Diagnostics Market: Country Business Analysis

  • 8.1. North America
    • 8.1.1. North America Molecular Diagnostics Market, 2018 - 2030 (USD Million)
    • 8.1.2. U.S.
      • 8.1.2.1. Key Country Dynamics
      • 8.1.2.2. Target Disease Prevalence
      • 8.1.2.3. Competitive Scenario
      • 8.1.2.4. Regulatory Framework
      • 8.1.2.5. U.S. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
    • 8.1.3. Canada
      • 8.1.3.1. Key Country Dynamics
      • 8.1.3.2. Target Disease Prevalence
      • 8.1.3.3. Competitive Scenario
      • 8.1.3.4. Regulatory Framework
      • 8.1.3.5. Canada Molecular Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 9. North America Molecular Diagnostics Market: Competitive Landscape

  • 8.1. Participant Categorization
    • 9.1.1. BD
      • 9.1.1.1. Overview
      • 9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.1.3. Product Benchmarking
      • 9.1.1.4. Strategic Initiatives
    • 9.1.2. Bio-Rad Laboratories, Inc.
      • 9.1.2.1. Overview
      • 9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.2.3. Product Benchmarking
      • 9.1.2.4. Strategic Initiatives
    • 9.1.3. Abbott
      • 9.1.3.1. Overview
      • 9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.3.3. Product Benchmarking
      • 9.1.3.4. Strategic Initiatives
    • 9.1.4. Agilent Technologies, Inc.
      • 9.1.4.1. Overview
      • 9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.4.3. Product Benchmarking
      • 9.1.4.4. Strategic Initiatives
    • 9.1.5. Danaher
      • 9.1.5.1. Overview
      • 9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.5.3. Product Benchmarking
      • 9.1.5.4. Strategic Initiatives
    • 9.1.6. Hologic Inc. (Gen Probe)
      • 9.1.6.1. Overview
      • 9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.6.3. Product Benchmarking
      • 9.1.6.4. Strategic Initiatives
    • 9.1.7. Illumina, Inc.
      • 9.1.7.1. Overview
      • 9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.7.3. Product Benchmarking
      • 9.1.7.4. Strategic Initiatives
    • 9.1.8. Johnson & Johnson Services, Inc.
      • 9.1.8.1. Overview
      • 9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.8.3. Product Benchmarking
      • 9.1.8.4. Strategic Initiatives
    • 9.1.9. Thermo Fisher Scientific Inc.
      • 9.1.9.1. Overview
      • 9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.9.3. Product Benchmarking
      • 9.1.9.4. Strategic Initiatives
    • 9.1.10. F. Hoffmann-La Roche, Ltd.
      • 9.1.10.1. Overview
      • 9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.10.3. Product Benchmarking
      • 9.1.10.4. Strategic Initiatives
  • 9.2. Participant's Overview
  • 9.3. Financial Performance
  • 9.4. Product Benchmarking
  • 9.5. Company Market Share Analysis, 2023
  • 9.6. Strategy Mapping
    • 9.6.1. Expansion
    • 9.6.2. Acquisition
    • 9.6.3. Product/Service Launch
    • 9.6.4. Others

Chapter 10. Analyst View

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Molecular Diagnostics Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Molecular Diagnostics Market, By Product, 2018 - 2030 (USD Million)
  • Table 5 North America Molecular Diagnostics Market, By Test Location, 2018 - 2030 (USD Million)
  • Table 6 North America Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 7 North America Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)
  • Table 8 U.S. Molecular Diagnostics market, by Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Molecular Diagnostics market, by Test Location, 2018 - 2030 (USD Million)
  • Table 10 U.S. Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)
  • Table 12 Canada Molecular Diagnostics market, by Product, 2018 - 2030 (USD Million)
  • Table 13 Canada Molecular Diagnostics market, by Test Location, 2018 - 2030 (USD Million)
  • Table 14 Canada Molecular Diagnostics Market, By Technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Molecular Diagnostics market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 North America molecular diagnostics market segmentation
  • Fig. 8 Market snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT analysis
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 North America molecular diagnostics market: Product movement analysis
  • Fig. 16 Instruments market, 2018 - 2030 (USD Million)
  • Fig. 17 Reagents market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 North America molecular diagnostics market: Test location movement analysis
  • Fig. 20 Point of care market, 2018 - 2030 (USD Million)
  • Fig. 21 Self-test or OTC market, 2018 - 2030 (USD Million)
  • Fig. 22 Central laboratories market, 2018 - 2030 (USD Million)
  • Fig. 23 North America molecular diagnostics market: Technology movement analysis
  • Fig. 24 PCR market, 2018 - 2030 (USD Million)
  • Fig. 25 Nucleic Acid Extraction PCR market, 2018 - 2030 (USD Million)
  • Fig. 26 Others PCR market, 2018 - 2030 (USD Million)
  • Fig. 27 Multiplex PCR market, 2018 - 2030 (USD Million)
  • Fig. 28 Other PCR market, 2018 - 2030 (USD Million)
  • Fig. 29 In Situ Hybridization market, 2018 - 2030 (USD Million)
  • Fig. 30 Isothermal Nucleic Acid Amplification Technology (INAAT) market, 2018 - 2030 (USD Million)
  • Fig. 31 Chips and microarrays market, 2018 - 2030 (USD Million)
  • Fig. 32 Mass spectrometry market, 2018 - 2030 (USD Million)
  • Fig. 33 Sequencing market, 2018 - 2030 (USD Million)
  • Fig. 34 Transcription mediated amplification market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 North America molecular diagnostics market: Application movement analysis
  • Fig. 37 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 38 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 39 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 40 Colorectal cancer market, 2018 - 2030 (USD Million)
  • Fig. 41 Cervical cancer market, 2018 - 2030 (USD Million)
  • Fig. 42 Kidney cancer market, 2018 - 2030 (USD Million)
  • Fig. 43 Liver cancer market, 2018 - 2030 (USD Million)
  • Fig. 44 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 45 Lung cancer market, 2018 - 2030 (USD Million)
  • Fig. 46 Other cancer market, 2018 - 2030 (USD Million)
  • Fig. 47 Pharmacogenomics market, 2018 - 2030 (USD Million)
  • Fig. 48 Infectious disease market, 2018 - 2030 (USD Million)
  • Fig. 49 MRSA market, 2018 - 2030 (USD Million)
  • Fig. 50 Clostridium difficile market, 2018 - 2030 (USD Million)
  • Fig. 51 Vancomycin-resistant enterococci market, 2018 - 2030 (USD Million)
  • Fig. 52 Carbapenem-resistant bacteria testing market, 2018 - 2030 (USD Million)
  • Fig. 53 Flu market, 2018 - 2030 (USD Million)
  • Fig. 54 Respiratory syncytial virus (RSV) market, 2018 - 2030 (USD Million)
  • Fig. 55 Candida market, 2018 - 2030 (USD Million)
  • Fig. 56 Tuberculosis and drug-resistant TB market, 2018 - 2030 (USD Million)
  • Fig. 57 Meningitis market, 2018 - 2030 (USD Million)
  • Fig. 58 Gastro-intestinal panel testing market, 2018 - 2030 (USD Million)
  • Fig. 59 Chlamydia market, 2018 - 2030 (USD Million)
  • Fig. 60 Gonorrhea market, 2018 - 2030 (USD Million)
  • Fig. 61 HIV market, 2018 - 2030 (USD Million)
  • Fig. 62 Hepatitis C market, 2018 - 2030 (USD Million)
  • Fig. 63 Hepatitis B market, 2018 - 2030 (USD Million)
  • Fig. 64 Other infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 65 Genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 66 Newborn screening market, 2018 - 2030 (USD Million)
  • Fig. 67 Predictive and presymptomatic testing market, 2018 - 2030 (USD Million)
  • Fig. 68 Others market, 2018 - 2030 (USD Million)
  • Fig. 69 Neurological disease market, 2018 - 2030 (USD Million)
  • Fig. 70 Cardiovascular disease market, 2018 - 2030 (USD Million)
  • Fig. 71 Microbiology market, 2018 - 2030 (USD Million)
  • Fig. 72 Others market, 2018 - 2030 (USD Million)
  • Fig. 73 Regional marketplace: key takeaways
  • Fig. 74 Regional outlook, 2023 & 2030
  • Fig. 75 North America molecular diagnostics market: Country movement analysis.
  • Fig. 76 North America molecular diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. key country dynamics
  • Fig. 78 U.S. molecular diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 79 Canada key country dynamics
  • Fig. 80 Canada molecular diagnostics market, 2018 - 2030 (USD Million)